Page 3 - Open Label News Today

In a dose of 0·4 mg/kg tenecteplase yielded worse safety and functional outcomes compared with alteplase in a prematurely terminated study. The study failed to establish non-inferiority of...

Clinical trials are a central part of the drug and medical intervention development process. This article looks at open-label clinical trials in more detail.

/PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative...

CHARLOTTESVILLE, Va., Jan. 20, 2022 /PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer an...

/PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative...

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

22.12.2021 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV ... Seite 1

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse